


CROSS-BORDER IPO INDEX: GLOBAL 2019





"It has been an interesting year for the global capital markets as unexpected issues, both in the market and politically, have significantly impacted upon activity and investor sentiment.

While we entered 2019 on an optimistic note, underperformance of a number of larger listings coupled with heightened political issues saw a more muted end to the year than anticipated.

Despite these macro-environment factors, we saw some of the largest IPOs of all time, with issuers braving the elements to go public and raise capital ahead of what is expected to be a downturn in the global markets in 2020."

Koen VanhaerentsGlobal Chair, Capital Markets

TOP EXCHANGES FOR CROSS-BORDER IPOS





TOP CROSS-BORDER IPOS 2019

Issuer	Capital Raised (USD million)	Home Jurisdiction and Exchange
Alibaba Group Holding Ltd	11,247	China - HKSE
Huatai Securities Co Ltd	1,692	China - LSE
TRATON SE	1,577	Germany – OMX Stock
Shenwan Hongyuan Group Co Ltd	1,159	China - HKSE
Hansoh Pharm Grp Co Ltd	1,153	China - HKSE

TOP CROSS-BORDER SECTORS 2019





KEY GLOBAL DATA POINTS



- 35%
CHANGE IN
CAPITAL RAISED
CROSS-BORDER
IPOS







CROSS-BORDER IPO INDEX: ASIA PACIFIC 2019





"Uncertainty will always influence the markets, with few major financial centers escaping unscathed this year. While the disturbances in Hong Kong did hamper activity to a degree, performance remained relatively stable – as the infrastructure and investor base was still reliably there for issuers. Alibaba is a good example of this.

Going forward, we are set to see the 'battle of the exchanges' heat up, with recent regulation changes throughout the wider Asia Pacific region, coupled with the launch of the STAR market already luring listings away from, or at least providing more options in addition to, traditional venues such as Nasdag and NYSE."

Ivy Wong

Baker McKenzie's Head of Asia Pacific Capital Markets

TOP EXCHANGES FOR CROSS-BORDER IPOS





TOP CROSS-BORDER IPOS 2019

Issuer	Capital Raised (USD million)	Home Jurisdiction and Exchange
Alibaba Group Holding Ltd	11,247	China - HKEx
Shenwan Hongyuan Group Co Ltd	1,159	China - HKEx
Hansoh Pharm Grp Co Ltd	1,153	China - HKEx
Topsports Intl Hldg Ltd	1,008	China - HKEx
China Feihe Ltd	856	China - HKEx

TOP CROSS-BORDER SECTORS 2019





KEY ASIA PACIFIC DATA POINTS




- 25%
CHANGE IN
CAPITAL RAISED
CROSS-BORDER
IPOS

- 13%
CHANGE IN
CAPITAL RAISED
DOMESTIC
IPOS





CROSS-BORDER IPO INDEX: NORTH AMERICA 2019





"We started the year with high expectations for a number of planned tech unicorn IPOs with possible record valuations. While a number of these unicorns completed their IPOs, several have seen significant price declines due to investor concern with their business models or path and timing to future profitability. As a result, we have seen a number of companies delay their IPOs in order to streamline and focus their operations, reduce costs and attempt to forge a path to profitability.

Despite this, domestic capital raising in North America hit its highest level since 2014 and we expect to see the region continue to buck the global trend well into Q1 2020 as issuers look to list ahead of the 2020 elections."

Chris BartoliNorth America Chair, Capital Markets

TOP EXCHANGES FOR CROSS-BORDER IPOS





TOP CROSS-BORDER IPOS 2019

Issuer	Capital Raised (USD million)	Home Jurisdiction and Exchange
Douyu International Holdings	775	China - Nasdaq
Luckin Coffee Inc	645	China - Nasdaq
Genmab A/S	582	Denmark - Nasdaq
Subversive Capital Acq Corp	575	US – NEX Board
Intercorp Finl Svcs Inc	469	Peru - NYSE

TOP CROSS-BORDER SECTORS 2019





KEY NORTH AMERICA DATA POINTS



- 58%
CHANGE IN
CAPITAL RAISED
CROSS-BORDER
IPOS

31%
CHANGE IN
CAPITAL RAISED
DOMESTIC
IPOS





CROSS-BORDER IPO INDEX: EMEA 2019





"While Brexit continued to pummel cross-border activity in the region, there were pockets of success among domestic activity – with a number of exchanges including London, Riyadh, Frankfurt and Italy playing host to billion dollar listings.


We are finally set to see the debut offering from Aramco, which is expected to rocket the Tadawul to the top of the board.

It's been a real rollercoaster for the EMEA markets of late, but we can expect to see big things in 2021, as ongoing political and economic issues are finally put to bed, releasing pent-up demand."

Adam Farlow EMEA Chair, Capital Markets

TOP EXCHANGES FOR CROSS-BORDER IPOS





TOP CROSS-BORDER IPOS 2019

Issuer	Capital Raised (USD million)	Home Jurisdiction and Exchange
Huatai Securities Co Ltd	1,692	China - LSE
TRATON SE	1,577	Germany - OMX Stock
Airtel Africa PLC	687	UK - Nigeria
Marel HF	417	Iceland - EuronextAM
Global Fashion Group SA	205	Luxembourg - Frankfurt

TOP CROSS-BORDER SECTORS 2019





KEY EMEA DATA POINTS



- 27%
CHANGE IN
CAPITAL RAISED
CROSS-BORDER
IPOS

9%
CHANGE IN
CAPITAL RAISED
DOMESTIC
IPOS





GLOBAL BIOTECH AND PHARMA IPOS 2019






"Despite the higher risks that come with investing in what are usually pre-profit companies, venture capitalists have long played a significant role in biotech start-ups - with the promise of richer rewards driving investor sentiment.

A rather new trend we are seeing in this space is venture lending, where VCs and VC divisions of Big Pharma are lending funds to smaller biotech and healthtech companies instead of acquiring equity. This should go a long way in buoying these types of companies as we look set to enter a more volatile 2020 market."

Ben McLaughlin Head of Global Healthcare

TOP EXCHANGES FOR BIOTECH AND PHARMA IPOS \$410 \$210 \$1,115 39 NASDAQ Hong Kong (HKEx and HK GEM) Hong Kong (HKEx and HK GEM) Korea Exchange (KRX) **Proceeds in** Number (including KOSDAQ) Shanghai Stock Exchange **USD Million** of Issues Shanghai Stock Exchange Shenzhen Stock Exchange (including ChiNext and SME) \$3,323 Canadian Securities Exchange / \$4,569 Korea Exchange (KRX) (including KOSDAQ) 10 Shenzhen Stock Exchange (including ChiNext and SME)

TOP BIOTECH AND PHARMA IPOS 2019



KEY GLOBAL BIOTECH AND PHARMA DATA POINTS





CROSS-BORDER

BRIDGEBIO

PHARMA INC

NASDAO

O.4 BILLION